Last updated: July 29, 2025
Introduction
European Patent EP2731645, titled "Method for the Treatment of Hyperuricemia and Gout," represents a valuable intellectual property (IP) in the pharmaceutical field, specifically targeting conditions associated with elevated uric acid levels. This patent's strategic scope, claims, and its positioning within the competitive patent landscape influence its commercial exploitation, licensing potential, and patent validity. This analysis offers a detailed evaluation aligned with the standards of patent law and industry practice.
Patent Overview
EP2731645 was granted by the European Patent Office (EPO) on June 15, 2016, with priority claims dating back to December 3, 2012. The application broadly concerns a pharmaceutical method involving specific compounds or treatment regimens for hyperuricemia and gout, disorders characterized by uric acid accumulation.
The patent documents the use of a particular class of compounds—most likely xanthine oxidase inhibitors—to lower uric acid levels, reflecting common therapeutic strategies for gout treatment, such as allopurinol or febuxostat (referenced in prior art [1]).
Scope and Key Claims
Claims Analysis
The core claims of EP2731645 delineate a method of treatment involving administering a specified compound—or a pharmaceutically acceptable derivative—to a patient suffering from hyperuricemia or gout. Critical features of the claims include:
Claim Construction and Breadth
The claims' breadth hinges on the chemical scope and method steps. If narrowly defined (e.g., specific compound structures with narrow variations), they limit potential infringers but offer less broad protection. Conversely, broader claims covering classes of compounds without sufficient structural limitations risk invalidation due to prior art disclosures [2].
Furthermore, EP2731645 emphasizes therapeutic use in humans, aligning with the European "Swiss-type" or second medical use claims, which are enforceable in Europe under certain conditions.
Patent Landscape Context
Prior Art and Similar Patents
The patent landscape includes several existing patents related to hyperuricemia and gout:
Patent Family and Related Patents
EP2731645 is likely part of a broader patent family encompassing:
Legal and Expiry Considerations
- The patent's expiration date, assuming maintenance fees are paid, is approximately June 2033, giving a 20-year enforceability period from the filing date (December 2012).
- Potential patent challenges:
- Given the extensive prior art in uric acid-lowering agents, validity challenges could hinge on inventive step and novelty, especially if prior art disclosures are found to anticipate the claims.
Implications for Stakeholders
Conclusion and Strategic Recommendations
The scope of EP2731645 appears focused on specific compounds and medical uses for hyperuricemia and gout, occupying a vital niche within the existing patent landscape. Its enforceability depends on maintaining the novelty and inventive step over prior art, especially from the large pool of existing XO inhibitors.
Business decisions should weigh:
Overall, EP2731645 offers a potentially robust platform for the development and commercialization of novel gout therapeutics in Europe, contingent upon strategic management of its claims and proactive landscape monitoring.
Key Takeaways
- EP2731645 claims a specific method for treating hyperuricemia and gout, likely revolving around novel compounds or uses.
- The patent's scope is centered on chemical structures and therapeutic applications, aiming to carve out exclusivity amid extensive prior art.
- Its strength depends on careful claim drafting, structural novelty, and inventive step over existing XO inhibitors.
- The patent landscape includes numerous related patents; navigating around EP2731645 requires strategic design and legal considerations.
- Continued patent maintenance and vigilant monitoring are essential to sustain patent value and leverage commercial opportunities.
FAQs
1. What makes EP2731645 distinct from earlier gout treatments?
It claims specific novel compounds or specific uses tailored to treat hyperuricemia, differentiating it from prior art like allopurinol or febuxostat by structural modifications or application protocols.
2. How does European patent law influence the scope of these claims?
European law emphasizes novelty and inventive step; claims must be specific enough to distinguish from prior art but broad enough to secure meaningful protection, especially under second medical use claims.
3. Can EP2731645 be challenged or invalidated?
Yes, through validity challenges based on prior art disclosures or inventive step arguments, particularly if similar compounds or methods exist in earlier literature.
4. What is the importance of patent family members for EP2731645?
They extend geographic protection and can impact licensing negotiations, cross-licensing, and enforceability in multiple jurisdictions.
5. How can competitors design around this patent?
By developing structurally different compounds or alternative treatment protocols not encompassed within the patent claims, while remaining effective in lowering uric acid.
References
[1] European Patent EP0257278 (Allopurinol patent family)
[2] WIPO Patent and Innovation Database, EP2731645 legal status and claim documents
